Papers/PMID:36683513
Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis.
Journal of Alzheimer's disease : JAD2023The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
choline — increases Mini-Mental State Examination total score
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“The pooled effect estimate showed that patients who received α-GPC and donepezil had significantly improved cognitive function than those who received donepezil and placebo as measured by MMSE (4 RCTs, MD: 1.72, 95% CI: 0.20 to 3.25, I2 = 61%, Fig. 3).”
Quoted verbatim from Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Dose
- choline alphoscerate (alpha-GPC) 1200 mg/day plus donepezil 10 mg/day versus placebo plus donepezil 10 mg/day
- Population
- Adults aged 50 years and older with neurological disorders and cognitive impairment (pooled RCTs); donepezil 10 mg/day given in both arms as background
Effect 1.72 mean difference, 95% CI 0.2 to 3.25
Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis.2023PMID:36683513Permalink